Embecta (NASDAQ:EMBC) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Embecta (NASDAQ:EMBC - Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.04, RTT News reports. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The firm had revenue of $259.00 million for the quarter, compared to the consensus estimate of $261.77 million. During the same period in the prior year, the firm posted $0.67 earnings per share. The firm's quarterly revenue was down 9.8% compared to the same quarter last year. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.

Embecta Trading Down 9.8 %

NASDAQ:EMBC traded down $1.30 during trading hours on Friday, hitting $12.00. 975,119 shares of the stock were exchanged, compared to its average volume of 449,042. The company has a market cap of $697.61 million, a P/E ratio of 12.00, a P/E/G ratio of 0.78 and a beta of 1.24. The firm's fifty day moving average price is $12.46 and its 200 day moving average price is $15.75. Embecta has a 52-week low of $10.83 and a 52-week high of $21.48.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Wednesday, May 28th will be issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 5.00%. Embecta's payout ratio is 60.00%.

Wall Street Analysts Forecast Growth

Separately, Mizuho began coverage on Embecta in a research note on Thursday, April 10th. They issued a "neutral" rating and a $15.00 price target for the company.

Insider Buying and Selling

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of Embecta stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the sale, the director now owns 36,133 shares of the company's stock, valued at $591,858.54. The trade was a 7.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.42% of the stock is owned by company insiders.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.